Michael Rosenblum

ORCID: 0000-0001-7411-4172
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Advanced Causal Inference Techniques
  • Statistical Methods in Clinical Trials
  • Statistical Methods and Inference
  • Health Systems, Economic Evaluations, Quality of Life
  • Statistical Methods and Bayesian Inference
  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Hidradenitis Suppurativa and Treatments
  • Colorectal and Anal Carcinomas
  • Intracerebral and Subarachnoid Hemorrhage Research
  • Chemotherapy-related skin toxicity
  • Acute Ischemic Stroke Management
  • Forensic and Genetic Research
  • Neurosurgical Procedures and Complications
  • Adolescent Sexual and Reproductive Health
  • Immune Cell Function and Interaction
  • Meta-analysis and systematic reviews
  • Dermatology and Skin Diseases
  • HIV/AIDS Research and Interventions
  • Autoimmune Bullous Skin Diseases
  • Optimal Experimental Design Methods
  • T-cell and B-cell Immunology
  • Mental Health Research Topics
  • Microscopic Colitis

Johns Hopkins University
2016-2025

University of California, San Francisco
2013-2025

Universitetshospitalernes Center for Sundhedsfaglig Forskning
2022-2025

Trex (United States)
2022

Yale University
2021

Informa (United Kingdom)
2021

Cornell University
2020

Weill Cornell Medicine
2020

City College of San Francisco
2015-2019

University of New Mexico
2019

Daniel F. Hanley Richard E. Thompson Michael Rosenblum Gayane Yenokyan Karen Lane and 95 more Nichol McBee Steven Mayo Amanda J. Bistran-Hall Dheeraj Gandhi W. Andrew Mould Natalie Ullman Hasan Ali J. Ricardo Carhuapoma Carlos S. Kase Kennedy R. Lees Jesse Dawson Alastair Wilson Joshua Betz Elizabeth A. Sugar Yi Hao Radhika Avadhani Jean-Louis Caron Mark R. Harrigan Andrew P. Carlson Diederik Bulters Didier Ledoux Judy Huang Cully A. Cobb Gaurav Gupta Ryan S. Kitagawa Michael R. Chicoine Hiren C. Patel Robert Dodd Paul J. Camarata Stacey Q Wolfe Agnieszka Stadnik Patricia Lynn Money Patrick Mitchell Rosario Sarabia Sagi Harnof Pál Barzó Andreas Unterberg Jeanne Teitelbaum Weimin Wang Craig S. Anderson A. D. Mendelow Barbara Gregson Scott Janis Paul Vespa Wendy Ziai Mario Zuccarello Issam A. Awad Azmil H. Abdul‐Rahim Amal Abou‐Hamden Michael Abraham Azam Ahmed Carlos Alarcon Alba E. François Aldrich David Altschul Sepideh Amin‐Hanjani Doug Anderson Safdar Ansari David Antezana Agnieszka Ardelt Fuat Arikán M. Báguena Alexandra Baker Steven J. Barrer Kyra J. Becker Thomas Bergman Azize Boström Jamie Braun Peter G. Brindley William C. Broaddus Robert H. Brown András Büki Bing Cao Ying Cao Julián Carrión‐Penagos Julio A. Chalela Tiffany Chang Indalecio Moran Chorro Shakeel A. Chowdhry Luisa Corral László Csiba Jason M. Davies Alberto Torres Díaz Colin P. Derdeyn Michael N. Diringer Rachel Dlugash Robert D. Ecker Tracey Economas Pedro Enríquez Erzsébet Ezer Yuhua Fan Hua Feng Douglas Franz William D. Freeman Matthew R. Fusco Walter Galicich

10.1016/s0140-6736(19)30195-3 article EN The Lancet 2019-02-10

Hidradenitis suppurativa (HS) is a debilitating chronic inflammatory skin disease characterized by abscess formation and development of multiple draining sinus tracts in the groin, axillae, perineum. Using proteomic transcriptomic approaches, we responses HS depth, revealing immune centered on IFN-γ, IL-36, TNF, with lesser contribution from IL-17A. We further identified B cells plasma cells, associated increases immunoglobulin production complement activation, as pivotal players...

10.1172/jci.insight.139930 article EN cc-by JCI Insight 2020-08-27

Triple-negative breast cancer (TNBC) represents a more aggressive and difficult subtype of where responses to chemotherapy occur, but toxicity is significant resistance often follows. Immunotherapy has shown promising results in various types cancer, including cancer. Here, we investigated new combination strategy histone deacetylase inhibitors (HDACi) are applied with immune checkpoint improve immunotherapy TNBC. Testing different epigenetic modifiers, focused on the mechanisms underlying...

10.18632/oncotarget.23169 article EN Oncotarget 2017-12-12

Experiencing systematic violence and trauma increases the risk of poor mental health outcomes; few interventions for these types exposures have been evaluated in low resource contexts. The objective this randomized controlled trial was to assess effectiveness two psychotherapeutic interventions, Behavioral Activation Treatment Depression (BATD) Cognitive Processing Therapy (CPT), reducing depression symptoms using a locally adapted validated version Hopkins Symptom Checklist dysfunction...

10.1186/s12888-014-0360-2 article EN cc-by BMC Psychiatry 2014-12-01

Hidradenitis suppurativa (HS) is a highly prevalent, morbid inflammatory skin disease with limited treatment options. The major cell types and pathways in of patients HS are poorly understood, which will respond to TNF-α blockade currently unknown. We discovered that clinically histologically healthy appearing (i.e., nonlesional skin) dysfunctional relative loss immune regulatory pathways. lesions were characterized by quantitative qualitative dysfunction type 2 conventional dendritic cells,...

10.1172/jci.insight.139932 article EN cc-by JCI Insight 2020-08-25

In addition to the accumulation of amyloid plaques and neurofibrillary tangles, presence excess neural activity is a pathological hallmark Alzheimer's disease (AD) prognostic indicator for progression AD pathology clinical/cognitive worsening in mild cognitive impairment due (MCI AD). The HOPE4MCI clinical study tested efficacy therapeutic with demonstrated ability normalize heightened hippocampus randomized controlled trial 78 weeks duration patients MCI AD.

10.1002/trc2.12446 article EN cc-by-nc-nd Alzheimer s & Dementia Translational Research & Clinical Interventions 2024-01-01

ABSTRACT Hidradenitis suppurativa (HS) is a relatively common and highly morbid inflammatory skin disease. Due to the limited understanding of HS's pathogenesis, there are currently insufficient treatment options available, many patients' medical needs not being met. This partly due historical scarcity ex vivo assays animal models that accurately recapitulate Thus, we have developed standardised whole‐tissue explant model HS examine its pathogenic mechanisms efficacy potential treatments...

10.1111/exd.70057 article EN cc-by-nc Experimental Dermatology 2025-02-01

We focus on estimating the average treatment effect in a randomized trial. If baseline variables are correlated with outcome, then appropriately adjusting for these can improve precision. An example is analysis of covariance (ANCOVA) estimator, which applies when outcome continuous, quantity interest difference mean outcomes comparing versus control, and linear model only main effects used. ANCOVA guaranteed to be at least as precise standard unadjusted asymptotically, under no parametric...

10.1002/sim.6507 article EN Statistics in Medicine 2015-04-14

Abstract “Covariate adjustment” in the randomized trial context refers to an estimator of average treatment effect that adjusts for chance imbalances between study arms baseline variables (called “covariates”). The could include, example, age, sex, disease severity, and biomarkers. According two surveys clinical reports, there is confusion about statistical properties covariate adjustment. We focus on analysis covariance (ANCOVA) estimator, which involves fitting a linear model outcome given...

10.1111/biom.13062 article EN Biometrics 2019-04-22

Time is of the essence in evaluating potential drugs and biologics for treatment prevention COVID-19. There are currently 876 randomized clinical trials (phase 2 3) treatments COVID-19 registered on clinicaltrials.gov. Covariate adjustment a statistical analysis method with to improve precision reduce required sample size substantial number these trials. Though covariate recommended by U.S. Food Drug Administration European Medicines Agency, it underutilized, especially types outcomes...

10.1111/biom.13377 article EN public-domain Biometrics 2020-09-26

Models, such as logistic regression and Poisson models, are often used to estimate treatment effects in randomized trials. These models leverage information variables collected before randomization, order obtain more precise estimates of effects. However, there is the danger that model misspecification will lead bias. We show certain easy compute, model-based estimators asymptotically unbiased even when working arbitrarily misspecified. Furthermore, these locally efficient. As a special case...

10.2202/1557-4679.1138 article EN The International Journal of Biostatistics 2010-01-01

Regression models are often used to test for cause-effect relationships from data collected in randomized trials or experiments. This practice has deservedly come under heavy scrutiny, because commonly such as linear and logistic regression will not capture the actual between variables, incorrectly specified potentially lead incorrect conclusions. In this article, we focus on hypothesis tests of whether treatment given a trial any effect mean primary outcome, within strata baseline variables...

10.1111/j.1541-0420.2008.01177.x article EN Biometrics 2009-02-07

INTRODUCTION: Ablation of Barrett's esophagus (BE) is the preferred approach for treatment neoplasia without visible lesions. Limited data on cryoballoon ablation (CBA) suggest its potential clinical utility. We evaluated safety and efficacy CBA in a multicenter study patients with neoplastic BE. METHODS: In prospective trial, 11 academic community centers recruited consecutive BE 1–6 cm length low-grade dysplasia, high-grade dysplasia (HGD), or intramucosal adenocarcinoma (ImCA) confirmed...

10.14309/ajg.0000000000000822 article EN cc-by-nc-nd The American Journal of Gastroenterology 2020-09-28
Coming Soon ...